Forest Laboratories Holdings Limited

Other

Richter Gedeon Nyrt.

Ironwood Pharmaceuticals, Inc.

Merz Pharma Gmbh & Co Kgaa

Pfizer Ireland Pharmaceuticals

Vermani, Kavita

Katdare, Ashok

Dedhiya, Mahendra, G.

Mahendra G Dedhiya

Mark G Currie

Anil Chhettry

Ranajoy Sarkar

Angelika Fretzen

Alain Bonnet

Alexandre Giuliani

Michael David Golden

Melanie Simone Ronsheim

Yuriy B Kalyan

Graham Richard Lawton

Shao Hong Zhou

Janette Cherryman

Alistair John Boyd

Saibaba Racha

Alexander Telford

Yun Mo

Andrew Phillips

Valérie Ravaux

Wattanaporn Abramowitz

Niranjan Rao

Brian Cali

Steven Richard Witowski

Brahma N Singh

Ahmad Hashash

Rahul Surana

Kavita Vermani

Ashok Katdare

Andreas Grill

Alain Priour

Ritesh Sanghvi

Véronique Ducandas

Peter Spargo

Sisir Bhattacharya

David Milne

Antonia Periclou

Alfredo Grossi

Shashank Mahashabde

Hong Zhao

Suneel K Rastogi

Bernhard Hauptmeier

Erhard Seiller

Rajiv Janjikhel

Yan Yang

Mohammad Mafruhul Bari

Wattanporn Abramowitz

Anshu Goel

Jeffrey Johnston

Matthew Miller

Valerie Ravaux

Veronique Ducandas

Bernard Joseph Lavins

Harvey Schneier

The present invention relates to stable and bioavailable immediate release formulations comprising dopamine receptor ligands. Methods of treating various disorders by administering the formulations are also described.

Pharmaceutical formulations containing dopamine receptor ligands

The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.

Stable formulations of linaclotide

The present invention provides pharmaceutical compositions given once daily containing at least one therapeutically active ingredient selected from the group consisting of memantine and a pharmaceutically acceptable salt of memantine, and a pharmaceutically acceptable polymeric matrix carrier. The dosage forms of the invention sustain the release of the therapeutically active agent from about 4 to about 24 hours when said dosage form is exposed to aqueous solutions. following entry of said form into a use environment, wherein said dosage form has a dissolution rate of more than about 80% after passage of about 6 hours to about 12 hours following said entry into said use environment.

Modified release formulations of memantine oral dosage forms

The present invention relates to compounds and processes for preparing compounds of Formula (I), 

Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof

The present invention relates to novel crystalline forms of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) thereof. The present invention relates to compositions comprising a crystalline form of sodium salt of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide (e.g., NXL-104) alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil). Processes for the preparation of the crystalline forms and methods of treating bacterial infections by administering the crystalline forms alone or in combination with an antibacterial agent (e.g., ceftaroline fosamil) are also described.

Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt

The present invention relates to novel crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide. Processes for the preparation of this form, compositions containing the form, and methods of use thereof are also described.

Crystalline forms of (1S,2R)-2-(amino methyl)-N,N-diethyl-1-phenyl cyclopropane carboxamide

Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-Diazabicyclo[3,2,1]octane-2-carboxamide sodium salt

Growing community of inventors

Pomona, NY, United States of America

Mahendra G Dedhiya